Supporting Addiction Treatment During COVID-19 (NAM-ASAM Collaboration)

4.8 (5 votes)

  • Register
    • Non-Member - Free!
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!
image


As the leader in developing clinical guidelines and standards in addiction medicine, ASAM takes its responsibility very seriously. Many providers and programs are urgently working to mitigate risks related to COVID-19. A joint series by the National Academy of Medicine (NAM) and the ASAM provides an overview of increasing COVID-19 resources and discusses evolving guidance to inform your practices during the pandemic. This is a 3 part series:  

  • WEBINAR 1: Helping patients in addiction treatment stay connected during the COVID pandemic- Recorded on May 2nd, 2020 11:00 am ET
  • WEBINAR 2: Challenges for Addiction Treatment across the Continuum of care- Recorded on May 22nd, 2020 2:30 pm ET
  • WEBINAR 3: Coordination across the social safety net to avert a crisis among patients with addiction- June 2, 2020 12:30 pm ET

  • Contains 4 Component(s), Includes Credits

    This session discusses unique challenges to substance use treatment providers and patients during the COVID-19 pandemic. This session will focus on addiction treatment considerations for Criminal Justice populations and populations experiencing homelessness during the COVID-19 pandemic.

    image

    Coordination Across the Social Safety Net to Avert a Crisis Among Patients with Addiction (NAM-ASAM)


    As the leader in developing clinical guidelines and standards in addiction medicine, ASAM takes its responsibility very seriously. Many providers and programs are urgently working to mitigate risks related to COVID-19. This joint NAM-ASAM session provides an overview of increasing COVID-19 resources and discusses evolving guidance to inform your practices during the pandemic. 

    This session is part of the ASAM-NAM webinar series, "Supporting Addiction Treatment During COVID-19" and this session is part 3 of the 3 part series. Previous webinars in the series can be found here.

    Session Information

    Date: Tuesday, June 2, 2020

    Time: 12:30 pm ET / 11:30 am CT/ 9:30 am PT

    Speakers

    • Yngvild K. Olsen, MD, MPH, Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services
    • Elizabeth Salisbury-Afshar, MD, MPH, Director, Center for Addiction Research and Effective Solutions, American Institutes for Research
    • Corey Waller, MD, Principal, Health Management Associates

    Learning Objectives

    By completing this session, you will be able to:

    • Discuss unique challenges to substance use treatment providers and patients during the COVID-19 pandemic. 
    • Recognize the enhanced risks as well as patient-centered strategies for maintaining access to addiction treatment for Criminal Justice populations and populations experiencing homelessness.
    • Describe strategies for infection mitigation and minimizing risks for patients and staff during the COVID-19 pandemic.
    • Identify successful strategies learned from on-the-ground experience working with populations experiencing homelessness and criminal justice populations.

    Yngvild K. Olsen

    MD, MPH, DFASAM

    Yngvild K. Olsen, MD, MPH, DFASAM graduated from Harvard Medical School in 1997, from the residency training program in internal medicine at Boston Medical Center in 2000, and from the Fellowship in General Internal Medicine at the Johns Hopkins School of Medicine in 2001. Dr. Olsen also serves as the Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services in Baltimore City. Dr. Olsen currently serves as Vice President of the American Society of Addiction Medicine and is a member of the Public Policy Committee. She is the Immediate Past President of the Maryland Society of Addiction Medicine, Immediate Past President of the Maryland Association for the Treatment of Opioid Dependence, and a Board member of the National Council on Alcoholism and Drug Dependence-MD (NCADD-MD). 

    No relevant financial disclosures

    Elizabeth M. Salisbury-Afshar

    MD, MPH, FAAFP, FACPM, DFASAM

    Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM is the Director of the Center for Addiction Research and Effective Solutions at the American Institute for Research, a nonprofit social and behavioral sciences research organization.  Dr. Salisbury-Afshar is board certified in family medicine, preventive medicine/public health and addiction medicine and her expertise lies at the intersection of these fields.  Past roles include serving as the Medical Director of Behavioral Health Systems Baltimore, a quasi-public entity that oversees all publicly funded addiction and mental health treatment and as the Medical Director of Behavioral Health at the Chicago Department of Public Health.  She has over ten years of experience working clinically in federally qualified health centers- providing direct patient care in both primary care and addiction medicine.  She previously served as the Medical Director of Heartland Alliance Health, a healthcare for the homeless provider in Chicago, and she continues to work in this clinic on a part-time basis and provides primary care and addiction treatment services.  Dr. Salisbury-Afshar received her Medical Degree from Rush University Medical College and her Master’s in Public Health from Johns Hopkins Bloomberg School of Public Health. 

    R. Corey Waller

    MD, MS, DFASAM

    R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neuromolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.

    Credits and Disclosures


    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ACCME Accreditation Statement

    This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine and The National Academy of Medicine (NAM). The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    The ASAM COVID-19 Review Team 

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ACCME’s Policy For Disclosures During The COVID-19 Pandemic

    Per ACCME’s simplified process for COVID-19, the requirement of disclosure of relevant financial relationships and resolution of personal conflicts of interest has been removed. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Hence, there is no possibility of a relevant financial relationship that would create a conflict of interest.

    Faculty and Panelists


    Kelly J. Clark, MD, MBA
    Immediate Past President, American Society of Addiction Medicine

    Elizabeth Finkelman, MPP
    Director, Action Collaborative on Countering the U.S. Opioid Epidemic, National Academy of Medicine

    Brian Hurley, MD, MBA
    Director of Addiction Medicine, Los Angeles County Department of Health Services

    Chris Bundy, MD, MPH
    Executive Medical Director, Washington Physicians Health Program

    Cortney Lovell, CRPA, CARC, RCP
    Recovery Coach and Co-Founder, Our Wellness Collective

  • Contains 4 Component(s), Includes Credits

    This session discusses unique challenges to substance use treatment providers and patients during the COVID-19 pandemic. The session will describe patient-centered strategies that can be used in a variety of settings, effective protocols for infection mitigation in outpatient and residential settings, and strategies to ensure coordination between different care settings.

    image

    Challenges for Addiction Treatment across the Continuum of Care (NAM-ASAM)


    As the leader in developing clinical guidelines and standards in addiction medicine, ASAM takes its responsibility very seriously. Many providers and programs are urgently working to mitigate risks related to COVID-19. This joint NAM-ASAM webinar recording provides an overview of increasing COVID-19 resources and discusses evolving guidance to inform your practices during the pandemic. 

    This session was recorded as part of the ASAM-NAM webinar series, "Supporting Addiction Treatment During COVID-10" and this session is part 2 of the 3 part series.

    Original Recording Information

    Date: Friday, May 22, 2020

    Time: 2:30 pm ET / 1:30 pm CT/ 11:30 am PT

    Speakers:

    • Kelly Clark, MD, MBA
    • Margaret Jarvis, MD, DFASAM 
    • Melissa Weimer, DO, MCR, FASAM 
    • Vincent G. Nelson, MD, MBA, FASA

    Learning Objectives

    By completing this session, you will be able to:

      • Discuss unique challenges to substance use treatment providers and patients during the COVID-19 pandemic.
      • Recognize patient-centered strategies for maintaining substance use treatments and services in a variety of settings including Opioid Treatment Programs (OTP), Office Based Opioid Treatment (OBOT), residential treatment programs, and acute care settings.
      • Describe effective protocols for infection mitigation in outpatient and residential settings.
      • Identify strategies to ensure effective protocols for coordination between different care settings during the COVID-19 pandemic.

    Kelly Clark

    MD, MBA, DFASAM, DFAPA

    Dr. Kelly J. Clark is the immediate past President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

    Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

    As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

    As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

    Margaret Jarvis

    MD, DFASAM

    Margaret Jarvism MD, DFASAM finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.

    Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.

    Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.

    Melissa B. Weimer

    DO, MCR, FASAM

    Melissa B. Weimer, DO, MCR, FASAM is board-certified in general internal medicine and addiction medicine and Assistant Professor of Medicine and Associate Program Director of the Addiction Medicine Fellowship at Yale University. She is an expert in hospital-based care for patients with substance use disorders and has worked with colleagues to develop successful hospital-based Addiction Medicine Consult Services at both Oregon Health & Science University and Yale University. Dr. Weimer is also a national leader in addiction medicine education and has developed curricula for safe opioid prescribing and addiction treatment through PCSS. Dr. Weimer serves of the national board of ASAM.

    Vincent Nelson

    MD, MBA, FASA

    Vincent Nelson, M.D., is vice president of Medical Affairs in the Office of Clinical Affairs (OCA) for the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield (BCBS) companies. The BCBS System is the nation’s largest health insurer covering one in three Americans. 

    Dr. Nelson provides clinical leadership across multiples disciplines, including quality management, provider recognition, medical policy, innovations of service delivery and strategic market opportunities. He ensures that the OCA and BCBSA incorporate clinical guidance that aligns with market demand and positively impacts the quality of healthcare while maintaining BCBS System leadership with members, providers and stakeholders. Prior to BCBSA, Dr. Nelson was a senior medical director/market chief medical officer for the Central/West U.S. Region at United Healthcare, where he partnered with senior leadership teams to lead market level programs, integrate clinical functions and drive results for clinical affordability, quality and population health measures.

    Previously, Dr. Nelson held the position of Assistant Professor in the Department of Anesthesiology, Critical Care, and Pain Medicine, at the University of Texas Health Science Center, McGovern Medical School in Houston, Texas. His interests and activities were in clinical care, teaching residents, and supporting department collaborations with industry sponsored pharmaceutical and medical device clinical trials. Before his careers in academia and industry, Dr. Nelson worked as a private practice clinician for 12½ years. He was a founding physician partner and board member of United States Anesthesia Partners (USAP).

    Dr. Nelson obtained his bachelor’s degree in biological sciences from Stanford University. He holds a master’s degree in business administration from Rice University, Jones School of Business, and a medical degree from the University of Chicago, Pritzker School of Medicine. He completed his Clinical Residency and Fellowship training at Harvard Medical School, in the Department of Anesthesiology, Pain Management, and Critical Care Medicine at Massachusetts General Hospital, Boston, Mass.

    Credits and Disclosures


    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ACCME Accreditation Statement

    This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine and The National Academy of Medicine (NAM). The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    The ASAM COVID-19 Review Team 

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ACCME’s Policy For Disclosures During The COVID-19 Pandemic

    Per ACCME’s simplified process for COVID-19, the requirement of disclosure of relevant financial relationships and resolution of personal conflicts of interest has been removed. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Hence, there is no possibility of a relevant financial relationship that would create a conflict of interest.

    Faculty and Panelists


    Kelly J. Clark, MD, MBA
    Immediate Past President, American Society of Addiction Medicine

    Elizabeth Finkelman, MPP
    Director, Action Collaborative on Countering the U.S. Opioid Epidemic, National Academy of Medicine

    Brian Hurley, MD, MBA
    Director of Addiction Medicine, Los Angeles County Department of Health Services

    Chris Bundy, MD, MPH
    Executive Medical Director, Washington Physicians Health Program

    Cortney Lovell, CRPA, CARC, RCP
    Recovery Coach and Co-Founder, Our Wellness Collective

  • Contains 5 Component(s), Includes Credits

    This session provides an overview of the NAM Action Collaborative on countering the U.S. Opioid Epidemic, discusses evolving ASAM COVID-19 guidance, and focuses on challenges and opportunities in the changing addiction medicine landscape.

    image

    Helping Patients in Addiction Treatment Stay Connected During the COVID-19 Pandemic (NAM-ASAM)


    As the leader in developing clinical guidelines and standards in addiction medicine, ASAM takes its responsibility very seriously. Many providers and programs are urgently working to mitigate risks related to COVID-19. This joint NAM-ASAM session provides an overview of increasing COVID-19 resources and discusses evolving guidance to inform your practices during the pandemic. 

    This session is part of the ASAM-NAM series, "Supporting Addiction Treatment During COVID-19" and this webinar is part 1 of the 3 part series.

    Original Recording Information

    Date: Thursday, May 7, 2020

    Time: 11:00 am ET / 10:00 am CT/ 8:00 am PT

    Speakers: 

    • Kelly Clark, MD, MBA
    • Brian Hurley, MD, MBA
    • Chris Bundy, MD, MPH
    • Cortney Lovell, CRPA, CARC, RCP

    Learning Objectives

    By completing this webinar, you will be able to:

    • Discuss unique challenges to substance use treatment providers and patients during the COVID-19 pandemic
    • Recognize patient-centered strategies for maintaining access to addiction treatment
    • Identify recent changes to telehealth regulations, payment, and clinical guidance related to access to medications and support groups
    • Describe strategies to ensure patients remain connected with their providers, treatment and recovery plans during the COVID-19 pandemic

    Kelly Clark (Moderator)

    MD, MBA, DFASAM, DFAPA

    Dr. Kelly J. Clark is the immediate past President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

    Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

    As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

    As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

    Brian Hurley

    MD, MBA, DFASAM

    Los Angeles Country Department of Health Services

    Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Director of Addiction Medicine for the Los Angeles County Department of Health Services. As Director-at-Large, Brian currently serves as a board member of ASAM and gives presentations around the world regarding addiction medicine. He co-chairs the Los Angeles County Department of Health Services’ Substance Use Disorders Workgroup and the SafeMedLA Medications for Addiction Treatment Action Team, and is the Clinical Director of the Treatment Starts Here program through the Center for Clinical Innovation, focused on increasing the delivery of medications for addiction treatment in California’s community health centers. 

    He is a senior researcher at the Friends Research Institute and is a primary investigator on a Tobacco Related Disease Prevention Program-funded project integrating smoking cessation services into community mental health centers and patient-centered medical homes and is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. 

    He is also a co-investigator for several Rand Corporation projects evaluating the integration of substance use disorder treatment within community mental health and Federally Qualified Health Center settings. He also serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry Examination Writing Committee. Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA) and is an alumnus of the Massachusetts General Hospital and McLean Hospital Psychiatry Residency Training Program and the New York University Addiction Psychiatry Fellowship. Additionally, he has served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine.

    No Relevant Financial Disclosures 

    Chris Bundy, MD, MPH

    Executive Medical Director, Washington Physicians Health Program

    Dr. Bundy is the Executive Medical Director of the Washington Physicians Health Program (WPHP), President of the Federation of State Physician Health Programs and Clinical Associate Professor of Psychiatry, University of Washington School of Medicine. Prior to joining WPHP, he served as Mental Health Service Chief and Chief of Psychiatry at the VA Puget Sound Healthcare System.  Dr. Bundy draws on his experience as a health-care leader, medical educator, and recovering physician to support education and advocacy efforts related to physician health and wellbeing.

    Cortney Lovell, CRPA, CARC, RCP

    Recovery Coach, and Co-Founder, Our Wellness Collective

    Widely regarded as one of the world’s top leaders in Recovery Coaching, Cortney Lovell is a modern messenger for change. Driven by her personal experience of growth and transformation, study and reflection, she is challenging traditional treatment systems to truly meet individuals who use drugs where they are, with the support they need. Cortney co-founded Our Wellness Collective and RecoveryTraining.Online to better support the growing recovery profession. She currently serves on the Health and Human Services Advisory Committee for Women’s Services, National Academy of Medicine’s Opioid Collaborative, is the Director of Cross Systems Education for Families Together in New York State and a regular addiction media correspondent.

    Credits and Disclosures


    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ACCME Accreditation Statement

    This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine and The National Academy of Medicine (NAM). The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    The ASAM COVID-19 Review Team 

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ACCME’s Policy For Disclosures During The COVID-19 Pandemic

    Per ACCME’s simplified process for COVID-19, the requirement of disclosure of relevant financial relationships and resolution of personal conflicts of interest has been removed. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Hence, there is no possibility of a relevant financial relationship that would create a conflict of interest.

    Faculty and Panelists


    Kelly J. Clark, MD, MBA
    Immediate Past President, American Society of Addiction Medicine

    Elizabeth Finkelman, MPP
    Director, Action Collaborative on Countering the U.S. Opioid Epidemic, National Academy of Medicine

    Brian Hurley, MD, MBA
    Director of Addiction Medicine, Los Angeles County Department of Health Services

    Chris Bundy, MD, MPH
    Executive Medical Director, Washington Physicians Health Program

    Cortney Lovell, CRPA, CARC, RCP
    Recovery Coach and Co-Founder, Our Wellness Collective

ACCME Accredited with Commendation

CME/CE Credits

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification (MOC)

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 4.5 LLSA credit towards ABPM MOC Part II requirements.

ABA Maintenance of Certification (MOC)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

ABP Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 4.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

 ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABAM Transitional Maintenance of Certification (Tmoc)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ACCME’s Policy For Disclosures During The COVID-19 Pandemic

Per ACCME’s simplified process for COVID-19, the requirement of disclosure of relevant financial relationships and resolution of personal conflicts of interest has been removed. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Hence, there is no possibility of a relevant financial relationship that would create a conflict of interest.